ClinicalTrials.gg

Program

AK3280

A development code.

Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by Shanghai Ark Biopharmaceutical.

Furthest: phase 3, since Jul 17, 20264 company-led studies, 1 open or runningNext primary completion: Sep 30, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Ark Biopharmaceutical41 open or runningphase 3since Jul 17, 2026Jun 12, 2019Sep 30, 2028phase 3 · NCT07719023

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 12, 2019First study: phase 1 study in HealthyFirst studyNCT03990688 · 48 enrolled · Sweden
  2. Jun 7, 2021Phase 1 study in HealthyNCT04926116 · 24 enrolled · China
  3. May 9, 2022Phase 2 study in Idiopathic Pulmonary FibrosisNCT05424887 · 105 enrolled · China
  4. Jul 17, 2026Phase 3 study in Idiopathic Pulmonary FibrosisPhase 3 reachedNCT07719023 · 263 planned · China

Ahead

  1. Sep 30, 2028Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisNCT07719023

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07719023Idiopathic Pulmonary Fibrosis · China3Not yet recruitingSep 30, 2028263
NCT05424887Idiopathic Pulmonary Fibrosis · China2UNKNOWNJul 2024105
NCT04926116Healthy · China1CompletedSep 28, 202124
NCT03990688Healthy · Sweden1CompletedSep 9, 202048

How it is read

Names in the registry

  • “AK3280”, 4 entries

Codes read as this program: AK3280.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.